Nonsurgical management of congenital eyelid malpositions using hyaluronic Acid gel.

Published

Journal Article

PURPOSE: To report our preliminary experience using hyaluronic acid gel fillers as a nonsurgical alternative in the management of congenital eyelid malpositions. METHODS: In this retrospective interventional case series, 5 patients (10 eyes) with congenital eyelid malpositions, including eyelid retraction, ectropion, euryblepharon, epiblepharon, and abnormalities associated with a shallow orbit, with resultant lagophthalmos and/or keratopathy and tearing were evaluated before and after injection with hyaluronic acid gel (Restylane) in the pretarsal and/or septal regions of the affected eyelid(s). Pretreatment, posttreatment, and follow-up photographs were analyzed for eyelid position and degree of eyelid closure and lagophthalmos, and slit-lamp evaluation of the degree of keratopathy. RESULTS: All 5 patients demonstrated significant improvement of eyelid position and degree of keratopathy. The mean improvement in lagophthalmos was 4.5 mm (range, 2-7 mm). The average volume of hyaluronic acid gel used was 0.5 ml per eyelid. Complications were minor, including transient edema and ecchymosis at the sites of injection. Of the 10 eyelids injected, only one had increased astigmatism after injection. CONCLUSIONS: Hyaluronic acid gel shows promise as a safe and effective nonsurgical treatment for the management of certain eyelid malpositions, disorders traditionally requiring surgical intervention if aggressive ocular lubrication fails. This treatment is particularly useful in such patients who are commonly premature with poor general health and serves as a temporizing measure by allowing the much needed tissue expansion to take effect over time.

Full Text

Duke Authors

Cited Authors

  • Taban, M; Mancini, R; Nakra, T; Velez, FG; Ela-Dalman, N; Tsirbas, A; Douglas, RS; Goldberg, RA

Published Date

  • July 2009

Published In

Volume / Issue

  • 25 / 4

Start / End Page

  • 259 - 263

PubMed ID

  • 19617780

Pubmed Central ID

  • 19617780

Electronic International Standard Serial Number (EISSN)

  • 1537-2677

Digital Object Identifier (DOI)

  • 10.1097/IOP.0b013e3181ac984b

Language

  • eng

Conference Location

  • United States